Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

38.17 +2.95 (+8.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Viking Therapeutics: High Risk, High Reward Play
Via MarketBeat
Here's Why This Obesity Drug Company's Share Price Soared Today
The company had positive updates on its clinical trials. 
Via The Motley Fool
Topics Earnings
Why Is Viking Therapeutics Stock Rising Today?
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials. 
Via Benzinga
Earnings Preview For Viking Therapeutics
 
Via Benzinga
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts
Via Stocktwits
Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside
Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating. 
Via Stocktwits
Topics Artificial Intelligence
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies
Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests. 
Via Investor's Business Daily
Viking Therapeutics (NASDAQ:VKTX) Reports Q3 2025 Earnings Miss and 2.8% After-Hours Decline
Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track. 
Via Chartmill
Topics Earnings
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck. 
Via Benzinga
Earnings Scheduled For October 22, 2025
 
Via Benzinga
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond
These companies are jockeying for position in a potential $150 billion market opportunity. 
Via The Motley Fool
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?
These stocks have climbed in the triple digits over the past few years. 
Via The Motley Fool
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?
The smaller drugmaker is looking to disrupt a fast-growing market. 
Via The Motley Fool
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
Why Shares in Viking Therapeutics Surged This Week
The small-cap pharmaceutical company may be the next in line as takeover fever heats up. 
Via The Motley Fool
The Best Stocks to Invest $1,000 in Right Now
Buying these three stocks offers you instant diversification. 
Via The Motley Fool
Topics Artificial Intelligence
Why This Beaten-Down GLP-1 Stock Could Be a Steal
There's more to this company than its performance on the stock market this year suggests. 
Via The Motley Fool
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking. 
Via The Motley Fool
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
6 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months
Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors. 
Via The Motley Fool
Topics Bankruptcy
Biotech Breakouts: 3 Stocks With Massive Upside Potential
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential 
Via MarketBeat
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
Peering Into Viking Therapeutics's Recent Short Interest
 
Via Benzinga
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.